adrenal gland neoplasms

Summary

Summary: Tumors or cancer of the ADRENAL GLANDS.

Top Publications

  1. ncbi Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
    Iñaki Comino-Méndez
    Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre CNIO, Madrid, Spain
    Nat Genet 43:663-7. 2011
  2. ncbi An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis
    Francien H van Nederveen
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, Netherlands
    Lancet Oncol 10:764-71. 2009
  3. ncbi Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations
    Hartmut P H Neumann
    Department of Nephrology and Hypertension, Albert Ludwigs University, Freiburg, Germany
    JAMA 292:943-51. 2004
  4. ncbi Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma
    Nelly Burnichon
    INSERM, UMR970, Paris Cardiovascular Research Center, F 75015 Paris, France
    Hum Mol Genet 20:3974-85. 2011
  5. ncbi Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas
    Elena López-Jiménez
    Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain
    Mol Endocrinol 24:2382-91. 2010
  6. ncbi Biochemical diagnosis of pheochromocytoma: which test is best?
    Jacques W M Lenders
    Department of Internal Medicine, St Radboud University Medical Center, Geert Grooteplein Zuid 8, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
    JAMA 287:1427-34. 2002
  7. ncbi Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features
    R Rossi
    Dipartimento di Endocrinologia, Universita di Napoli Federico II, Italy
    J Clin Endocrinol Metab 85:1440-8. 2000
  8. pmc Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature
    Lucia Martiniova
    Section on Medical Neuroendocrinology, Reproductive and Adult Endocrinology Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development NIH, 10 Center Drive MSC 1109, Bethesda, MD 20892 1109, USA
    Clin Exp Metastasis 26:239-50. 2009
  9. ncbi Clinical review: Diagnosis and treatment of subclinical hypercortisolism
    Iacopo Chiodini
    Department of Medical Sciences, University of Milan, Endocrinology and Diabetology Unit, Fondazione Ospedale Maggiore Policlinico, Istituto di Ricovero e Cura a Carattere Scientifico, Pad Granelli, Via F Sforza 35, 20122 Milan, Italy
    J Clin Endocrinol Metab 96:1223-36. 2011
  10. ncbi The diagnosis and management of malignant phaeochromocytoma and paraganglioma
    Alexandra Chrisoulidou
    Department of Endocrinology and Endocrine Oncology, Theagenion Hospital, Thessaloniki, Greece
    Endocr Relat Cancer 14:569-85. 2007

Research Grants

  1. PHEOCHROMOCYTOMAS FROM NEUROFIBROMATOSIS KNOCKOUT MICE
    Arthur Tischler; Fiscal Year: 2003
  2. CHROMAFFIN CELL PROLIFERATION IN NEOPLASTIC PROGRESSION
    Arthur Tischler; Fiscal Year: 2006
  3. TRAINING PROGRAM IN CLINICAL RESEARCH
    David Schteingart; Fiscal Year: 2004
  4. Michigan Mentored Clinical Scholars Program
    David Schteingart; Fiscal Year: 2007
  5. MINORITY PREDOCTORAL FELLOWSHIP PROGRAM
    HECTOR MOBINE; Fiscal Year: 2008
  6. HEART IMAGING AGENTS--STRUCTURAL MECHANISTICS STUDY
    David Raffel; Fiscal Year: 2001
  7. INHALATIONAL ANESTHETIC BINDING STUDIES
    Roderic Eckenhoff; Fiscal Year: 2007
  8. NFAT and MEF-2 Choreograph Bladder Wall Remodeling Following Partial Outlet Obstr
    STEPHEN ANTHONY ZDERIC; Fiscal Year: 2010
  9. Homologous Recombination in a Secretory Mouse Cell Line
    AMY HARKINS; Fiscal Year: 2003
  10. Microarray analysis of thyroid neoplasm
    Martha Zeiger; Fiscal Year: 2004

Detail Information

Publications301 found, 100 shown here

  1. ncbi Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
    Iñaki Comino-Méndez
    Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre CNIO, Madrid, Spain
    Nat Genet 43:663-7. 2011
    ....
  2. ncbi An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis
    Francien H van Nederveen
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, Netherlands
    Lancet Oncol 10:764-71. 2009
    ..We investigated whether SDHB immunohistochemistry could effectively discriminate between SDH-related and non-SDH-related phaeochromocytomas and paragangliomas in large retrospective and prospective tumour series...
  3. ncbi Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations
    Hartmut P H Neumann
    Department of Nephrology and Hypertension, Albert Ludwigs University, Freiburg, Germany
    JAMA 292:943-51. 2004
    ..In both syndromes, pheochromocytomas as well as head and neck paragangliomas occur; however, details for individual risks and other clinical characteristics are unknown...
  4. ncbi Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma
    Nelly Burnichon
    INSERM, UMR970, Paris Cardiovascular Research Center, F 75015 Paris, France
    Hum Mol Genet 20:3974-85. 2011
    ..Altogether, these new findings suggest that somatic mutation analysis is likely to yield important clues for personalizing molecular targeted therapies...
  5. ncbi Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas
    Elena López-Jiménez
    Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain
    Mol Endocrinol 24:2382-91. 2010
    ..These findings pave the way for more specific therapeutic approaches for malignant PCCs/PGLs management based on the patient's genetic alteration...
  6. ncbi Biochemical diagnosis of pheochromocytoma: which test is best?
    Jacques W M Lenders
    Department of Internal Medicine, St Radboud University Medical Center, Geert Grooteplein Zuid 8, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
    JAMA 287:1427-34. 2002
    ..Diagnosis of pheochromocytoma depends on biochemical evidence of catecholamine production by the tumor. However, the best test to establish the diagnosis has not been determined...
  7. ncbi Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features
    R Rossi
    Dipartimento di Endocrinologia, Universita di Napoli Federico II, Italy
    J Clin Endocrinol Metab 85:1440-8. 2000
    ..These findings support the hypothesis that clinically silent hypercortisolism is probably not completely asymptomatic...
  8. pmc Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature
    Lucia Martiniova
    Section on Medical Neuroendocrinology, Reproductive and Adult Endocrinology Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development NIH, 10 Center Drive MSC 1109, Bethesda, MD 20892 1109, USA
    Clin Exp Metastasis 26:239-50. 2009
    ..Microarray gene expression comparison and quantitative real-time PCR of these more aggressive cells to the MPC-parental cell line identified genes that may be important for the metastatic process...
  9. ncbi Clinical review: Diagnosis and treatment of subclinical hypercortisolism
    Iacopo Chiodini
    Department of Medical Sciences, University of Milan, Endocrinology and Diabetology Unit, Fondazione Ospedale Maggiore Policlinico, Istituto di Ricovero e Cura a Carattere Scientifico, Pad Granelli, Via F Sforza 35, 20122 Milan, Italy
    J Clin Endocrinol Metab 96:1223-36. 2011
    ..The present manuscript reviews the literature on diagnostic procedures and the metabolic effect of the recovery from SH...
  10. ncbi The diagnosis and management of malignant phaeochromocytoma and paraganglioma
    Alexandra Chrisoulidou
    Department of Endocrinology and Endocrine Oncology, Theagenion Hospital, Thessaloniki, Greece
    Endocr Relat Cancer 14:569-85. 2007
    ..Ongoing microarray studies may provide novel intracellular pathways of importance for proliferation/cell cycle control, and lead to the development of novel pharmacological agents...
  11. ncbi State-of-the-art adrenal imaging
    W W Mayo-Smith
    Department of Radiology of Brown University, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903, USA
    Radiographics 21:995-1012. 2001
    ..Certain features can be used by the radiologist to establish a definitive diagnosis for most adrenal masses (including carcinoma, infections, and hemorrhage) based on imaging findings alone...
  12. ncbi Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients
    Zoran Erlic
    Department of Nephrology, Section of Preventive Medicine, Albert Ludwigs University, Hugstetter Strasse 55, Freiburg, Germany
    Clin Cancer Res 15:6378-85. 2009
    ..The aim of the study is to systematically obtain a robust algorithm to identify who should be genetically tested, and to determine the order in which genes should be tested...
  13. ncbi Genetics of pheochromocytoma and paraganglioma in Spanish patients
    Alberto Cascon
    Hereditary Endocrine Cancer Group, Institute de Salud Carlos III Center for Biomedical Research on Rare Diseases, Madrid, Spain
    J Clin Endocrinol Metab 94:1701-5. 2009
    ..In these cases, other clinical aspects like bilaterality, multiplicity, location of the tumors, or age at onset can help to recognize the underlying genes involved...
  14. ncbi Animal models of pheochromocytoma
    A S Tischler
    Department of Pathology, Tufts University School of Medicine, Tufts New England Medical Center, Boston, MA 02111, USA
    Histol Histopathol 19:883-95. 2004
    ..Understanding of factors that permit pheochromocytoma cells to proliferate might itself provide important insights for tumor biology...
  15. ncbi Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?
    T J Cawood
    Department of Endocrinology, Christchurch Hospital, Private Bag 4710, Christchurch, New Zealand
    Eur J Endocrinol 161:513-27. 2009
    ..Surgical series, histopathological series and oncological series were reviewed and most were excluded...
  16. ncbi Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes
    Anthony J Gill
    Department of Anatomical Pathology, Royal North Shore Hospital, Sydney 2065, Australia
    Hum Pathol 41:805-14. 2010
    ..Completely absent staining is more commonly found with SDHB mutation, whereas weak diffuse staining often occurs with SDHD mutation...
  17. ncbi Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies
    Svenja Nölting
    Department of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Endocr Pathol 23:21-33. 2012
    ....
  18. ncbi Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism
    Iacopo Chiodini
    Department of Medical Sciences, University of Milan, 20122 Milan, Italy
    J Clin Endocrinol Metab 95:2736-45. 2010
    ..In patients with adrenal incidentalomas, subclinical hypercortisolism (SH) is associated with an increased prevalence of the metabolic syndrome. The effect of surgical/conservative approach is debated...
  19. ncbi Management of the clinically inapparent adrenal mass ("incidentaloma")
    Melvin M Grumbach
    University of California, San Francisco, San Francisco, California, USA
    Ann Intern Med 138:424-9. 2003
    ..The panel also advocated a multidisciplinary approach to managing adrenal incidentalomas. The statement is an independent report of the panel and is not a policy statement of the National Institutes of Health or the federal government...
  20. ncbi 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation
    Catherine Ansquer
    Service de Medecine Nucleaire, CHU Hotel Dieu, Nantes, France
    Eur J Nucl Med Mol Imaging 37:1669-78. 2010
    ..This prospective multicentre study assesses the usefulness of FDG PET/CT in characterizing and making the therapeutic decision concerning adrenal tumours that are suspicious or indeterminate in nature after conventional examinations (CE)...
  21. ncbi Adrenal incidentaloma: a diagnostic challenge
    Panagiotis Anagnostis
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Hormones (Athens) 8:163-84. 2009
    ..The present review considers the prevalence, pathology and natural history of AIs. We also discuss the reliability of available screening methods and localization techniques and consider optimal management and follow-up strategies...
  22. ncbi Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:717-25. 2011
    ..Pheochromocytomas and sympathetic paragangliomas are rare neuroendocrine tumors for which no precise histological or molecular markers have been identified to differentiate benign from malignant tumors...
  23. ncbi Array-comparative genomic hybridization in sporadic benign pheochromocytomas
    Francien H van Nederveen
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Endocr Relat Cancer 16:505-13. 2009
    ..In addition, genes on 21q and 22q might play a more important role in PCC pathogenesis than had been assumed thus far...
  24. ncbi Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2
    Andreas Machens
    Department of General, Visceral, and Vascular Surgery, Martin Luther University Halle Wittenberg, Ernst Grube Strasse 40, D 06097 Halle Saale, Germany
    J Clin Endocrinol Metab 90:3999-4003. 2005
    ..Recent data suggest a codon-specific, age-related development of multiple endocrine neoplasia type 2...
  25. ncbi Laparoscopic adrenalectomy for adrenal tumors in children: a case series
    Pablo Laje
    Department of Pediatric Surgery, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Laparoendosc Adv Surg Tech A 19:S27-9. 2009
    ..The aims of this study were to present our experience with children who underwent laparoscopic adrenalectomy for adrenal tumors over a 4-year period, discuss the technical aspects of the procedure, and review the current literature...
  26. ncbi Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study
    Antonio Toniato
    Surgical Pathology Clinic, Department of Medical and Surgical Sciences, University of Padua School of Medicine, Padova, Italy
    Ann Surg 249:388-91. 2009
    ....
  27. ncbi Adrenal incidentaloma: a new cause of the metabolic syndrome?
    Massimo Terzolo
    Dipartimento di Scienze Cliniche e Biologiche, Medicina Interna I, Clinica Medica, A S O San Luigi, 10043 Orbassano, Italy
    J Clin Endocrinol Metab 87:998-1003. 2002
    ..Midnight serum cortisol appears as a sensitive marker of the metabolic effects of subclinical Cushing's syndrome...
  28. ncbi Adrenal masses: characterization with combined unenhanced and delayed enhanced CT
    Elaine M Caoili
    Department of Radiology, University of Michigan Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109 9723, USA
    Radiology 222:629-33. 2002
    ..To assess the accuracy of a dedicated adrenal computed tomographic (CT) protocol...
  29. ncbi Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay
    Michael A Blake
    Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, White 270, 55 Fruit St, Boston, MA 02114, USA
    Radiology 238:578-85. 2006
    ....
  30. pmc Noninvasive monitoring of a murine model of metastatic pheochromocytoma: a comparison of contrast-enhanced microCT and nonenhanced MRI
    Lucia Martiniova
    Reproductive and Adult Endocrinology Program, National Institutes of Child Health and Human Development, Bethesda, Maryland 20892 1109, USA
    J Magn Reson Imaging 29:685-91. 2009
    ..However, the choice of imaging modality is still evolving...
  31. ncbi Pheochromocytoma: current approaches and future directions
    Joel T Adler
    Section of Endocrine Surgery, Department of Surgery, University of Wisconsin, Madison, Wisconsin, USA
    Oncologist 13:779-93. 2008
    ..In this review, we discuss the presentation, diagnosis, management, and future directions in the management of this disease...
  32. ncbi A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines
    Anna M Sawka
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 88:553-8. 2003
    ....
  33. ncbi Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice
    J F Powers
    Department of Pathology, Box 802, New England Medical Center and Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA
    Cell Tissue Res 302:309-20. 2000
    ..Mouse pheochromocytomas are a new tool for studying genes and signaling pathways that regulate cell growth and differentiation in adrenal medullary neoplasms and are a unique model for studying the regulation of PNMT expression...
  34. pmc Germline mutations in TMEM127 confer susceptibility to pheochromocytoma
    Yuejuan Qin
    Departments of Medicine, San Antonio, Texas, USA
    Nat Genet 42:229-33. 2010
    ..Our studies identify TMEM127 as a tumor suppressor gene and validate the power of hereditary tumors to elucidate cancer pathogenesis...
  35. ncbi The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma
    Henri J L M Timmers
    Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892 1109, USA
    J Nucl Med 48:1599-606. 2007
    ..The aim of this study was to investigate the sensitivity of (18)F-DOPA PET in the detection of paraganglioma and its metastatic lesions and to evaluate whether tracer uptake by the tumors is enhanced by carbidopa...
  36. ncbi Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas
    Kazuhiro Takekoshi
    Department of Clinical Pathology, Institute of Clinical Medicine, University of Tsukuba, 1 1 1 Tennoudai, Tsukuba, 305 8575, Japan
    Life Sci 74:863-71. 2004
    ..Therefore, we speculate that upregulation of VEGF expression and its receptors might be important in the pathogenesis of pheochromocytomas...
  37. ncbi Pheochromocytoma and extra-adrenal paraganglioma: updates
    Arthur S Tischler
    Department of Pathology, Tufts New England Medical Center, Boston, MA 02111, USA
    Arch Pathol Lab Med 132:1272-84. 2008
    ..These developments are concurrent with the publication and dissemination of the 2004 World Health Organization bluebook on pathology and genetics of endocrine tumors...
  38. ncbi Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization
    Giles W L Boland
    Department of Radiology, Massachusetts General Hospital, White Building 270C, 55 Fruit St, Boston, MA 02114, USA
    Radiology 249:756-75. 2008
    ..An imaging algorithm is provided to guide radiologists toward the appropriate test to make the correct diagnosis...
  39. ncbi Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas
    Anne Paule Gimenez-Roqueplo
    AP HP, Hopital Europeen Georges Pompidou, Département de Génétique Moléculaire, Paris
    Cancer Res 63:5615-21. 2003
    ..These data strongly suggest that SDHB gene is a tumor suppressor gene and that the identification of germ-line mutations in SDHB gene in patients with ASPs should be considered as a high-risk factor for malignancy or recurrence...
  40. ncbi Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis
    Tawee Tanvetyanon
    Biostatistics Division, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33613, USA
    J Clin Oncol 26:1142-7. 2008
    ..However, some suggest that the survival outcome among patients with a synchronous metastasis is poor. It remains unclear whether this treatment approach is warranted among those with synchronous metastasis...
  41. pmc Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma
    Henri J L M Timmers
    Reproductive and Adult Endocrinology Program, Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 94:4757-67. 2009
    ....
  42. pmc Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors
    Judith Favier
    Collège de France and Institut National de la Santé et de la Recherche Médicale U36, Paris, France
    Am J Pathol 161:1235-46. 2002
    ..Altogether, our observations show that analysis of angiogenesis provides promising new criteria for the diagnosis of malignant pheochromocytomas...
  43. ncbi Imaging of neuroendocrine tumors
    Vittoria Rufini
    Department of Nuclear Medicine, Universita Cattolica del Sacro Cuore, Rome, Italy
    Semin Nucl Med 36:228-47. 2006
    ..New somatostatin analogs with different receptor affinity as well as other peptides are currently under investigation and will further improve our diagnostic and therapeutic capabilities in the future...
  44. ncbi Recurrent genomic alterations in benign and malignant pheochromocytomas and paragangliomas revealed by whole-genome array comparative genomic hybridization analysis
    Johanna Sandgren
    Department of Surgical Sciences, Uppsala University Hospital Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Endocr Relat Cancer 17:561-79. 2010
    ....
  45. ncbi Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification
    Graeme Eisenhofer
    Institute of Clinical Chemistry and Laboratory Medicine and Department of Medicine III, University of Dresden, Fetscherstrasse 74, 01307, Dresden, Germany
    Endocr Pathol 23:4-14. 2012
    ....
  46. ncbi The genetics of phaeochromocytoma: using clinical features to guide genetic testing
    Mariam Jafri
    Centre for Rare Diseases and Personalised Medicine, The Medical School, Institute of Biomedical Research West, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Eur J Endocrinol 166:151-8. 2012
    ..Mutation carriers should be offered specific surveillance programmes (according to the relevant gene). In this review, we will describe the genetics of aPCA/eFPGL and strategies for genetic testing...
  47. ncbi Pheochromocytoma and functional paraganglioma
    Heather Yeo
    Department of General Surgery, Yale University School of Medicine, New Haven, CT 06520, USA
    Curr Opin Oncol 17:13-8. 2005
    ..It emphasizes current diagnostic and surgical approaches and discusses the potential for future developments in the field...
  48. ncbi Malignant pheochromocytoma: a review
    Avital Harari
    Department of Surgery, Division of Endocrine Surgery of University of California, San Francisco, CA 94115, USA
    Am J Surg 201:700-8. 2011
    ..In this review, we discuss the current information known of malignant pheochromocytomas...
  49. ncbi AME position statement on adrenal incidentaloma
    M Terzolo
    Medicine I, AOU San Luigi Gonzaga, University of Turin, Regione Gonzole 10, Orbassano 10043, Italy
    Eur J Endocrinol 164:851-70. 2011
    ..To assess currently available evidence on adrenal incidentaloma and provide recommendations for clinical practice...
  50. pmc Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892 1109, USA
    Cancer Lett 316:46-52. 2012
    ....
  51. ncbi The diagnosis and medical management of advanced neuroendocrine tumors
    Gregory A Kaltsas
    Department of Endocrinology, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
    Endocr Rev 25:458-511. 2004
    ..Maintenance of the quality of life should be a priority, particularly because patients with disseminated disease may experience prolonged survival...
  52. ncbi Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases
    Lester D R Thompson
    Department of Endocrine and Otorhinolaryngic Head and Neck Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
    Am J Surg Pathol 26:551-66. 2002
    ..Application of these criteria to a large cohort of cases will help to elucidate the accuracy of this grading system in clinical practice...
  53. ncbi From transcriptional profiling to tumor biology in pheochromocytoma and paraganglioma
    Alberto Cascon
    Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre CNIO, Madrid, Spain
    Endocr Pathol 23:15-20. 2012
    ..We also review the advances in our understanding of cluster 2 tumors, and in particular, focus on the newly described MAX tumors...
  54. ncbi From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors
    Wen T Shen
    Department of Surgery, University of California, San Francisco, California, USA
    J Surg Oncol 89:186-92. 2005
    ..We also discuss the choice of optimal surgical approach for performing adrenalectomy (laparoscopic, open, hand-assist)...
  55. pmc Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?
    Esther Korpershoek
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Room Ae304, P O Box 2040, 3000, CA, Rotterdam, The Netherlands
    Endocr Pathol 23:43-54. 2012
    ..These studies also indicate that some mouse models and both mouse PCC cell lines are suitable for testing new therapies for metastatic PCC...
  56. ncbi Wnt/β-catenin signalling in adrenal physiology and tumour development
    Annabel Berthon
    CNRS UMR6247, Génétique Reproduction et Développement, Clermont Universite, Aubiere, France
    Mol Cell Endocrinol 351:87-95. 2012
    ..This review will summarise all these recent findings and will focus on some of the mechanisms that may lead to aberrant accumulation of β-catenin in adrenocortical tumours...
  57. ncbi The many faces of pheochromocytoma
    H K Ghayee
    Division of Endocrinology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
    J Endocrinol Invest 31:450-8. 2008
    ..To recognize and manage pheochromocytomas in unusual settings...
  58. ncbi Incidentally discovered adrenal tumors: a lesson from observation of 1,444 patients
    A A Kasperlik-Załuska
    Department of Endocrinology, Centre for Postgraduate Medical Education, Warsaw, Poland
    Horm Metab Res 40:338-41. 2008
    ..The patients not qualified for surgery were carefully controlled by imaging and hormonal examinations. Malignancy is the most serious risk in the group of patients with incidentally discovered adrenal tumors...
  59. ncbi Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior
    Janos Geli
    Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
    Clin Cancer Res 14:2551-9. 2008
    ..This study aims to quantitatively assess promoter and global methylation changes in pheochromocytomas and abdominal paragangliomas and its relation to tumor phenotypes...
  60. ncbi Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors
    Noriko Kimura
    Department of Pathology and Laboratory Medicine, Tohoku Rosai Hospital, Japan Labor Health and Welfare Organization, 21 3 4 Dainohara Aoba ku Sendai 981 8563, Japan
    Endocr Pathol 16:23-32. 2005
    ..Differences between groups were statistically significant. The data show that using this grading scoring system for sympathetic paragangliomas correlates with both metastatic potential and patient survival...
  61. ncbi Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas
    Li Yao
    Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    JAMA 304:2611-9. 2010
    ..We recently identified germline mutations of the novel transmembrane-encoding gene FP/TMEM127 in familial and sporadic pheochromocytomas consistent with a tumor suppressor effect...
  62. pmc Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors
    Lucia Martiniova
    Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 1E 3140, 10 Center Drive MSC 1109, Bethesda, Maryland 20892 1109, USA
    Endocr Relat Cancer 18:143-57. 2011
    ..HDAC inhibitors may enhance the therapeutic efficacy of [(131)I]MIBG treatment in patients with advanced malignant pheochromocytoma and paraganglioma...
  63. ncbi Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas
    Diana E Benn
    Cancer Genetics, Kolling Institute of Medical Research, Royal North Shore Hospital, Syney, NSW, Australia
    Oncogene 22:1358-64. 2003
    ..Therefore, we conclude that SDHB has a major role in the pathogenesis of familial phaeochromocytomas, but the possible role of SDHB in sporadic tumours showing allelic loss at 1p36 has yet to be ascertained...
  64. ncbi Laparoscopic adrenalectomy, a safe procedure for pheochromocytoma. A retrospective review of clinical series
    Giovanni Conzo
    Department of Anaesthesiology, Surgical and Emergency Science, VII Division of General Surgery, Second University of Naples, Via Gen Giordano Orsini 42, 80132 Naples, Italy
    Int J Surg 11:152-6. 2013
    ....
  65. ncbi Extra-adrenal pheochromocytoma: diagnosis and management
    Grant I S Disick
    Department of Urology, The Mount Sinai Medical Center, One Gustave L Levy Place, Box 1272, New York, NY 10029, USA
    Curr Urol Rep 8:83-8. 2007
    ..Recent reports suggest that a laparoscopic approach, along with intraoperative ultrasound, can safely remove these tumors. EAPs recur and metastasize more often than their adrenal counterparts, making lifelong follow-up essential...
  66. ncbi SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling
    Annika Blank
    Institute of Pathology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Endocr Relat Cancer 17:919-28. 2010
    ..The lack of correlation of SDHB loss with classic hypoxia signals argues against the current hypoxia hypothesis in malignant PCC/PGL. We suggest SDHB protein loss as a marker of adverse outcome both in sporadic and in familial PCC/PGL...
  67. ncbi MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas
    Zsófia Tömböl
    Faculty of Medicine, 2nd Department of Medicine, Semmelweis University, Budapest, Hungary
    Mod Pathol 23:1583-95. 2010
    ..MicroRNA expression patterns differ between various sporadic, hereditary and recurring tumors and miR-1225-3p may be useful for identifying recurring pheochromocytomas...
  68. ncbi Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma
    Shawn D Safford
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Surgery 134:956-62; discussion 962-3. 2003
    ..We report our institutional experience for the treatment of metastatic pheochromocytoma and paraganglioma...
  69. ncbi Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience
    Peter J Mazzaglia
    Rhode Island Hospital, Warren Alpert School of Medicine, Brown University, Providence, RI 02906, USA
    Arch Surg 144:465-70. 2009
    ..To determine the value of percutaneous adrenal biopsy in the evaluation of adrenal neoplasm...
  70. ncbi Retroperitoneal extraadrenal myelolipoma: Technetium-99m sulfur colloid scintigraphy and CT imaging
    Ba D Nguyen
    Department of Radiology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Clin Nucl Med 32:135-8. 2007
  71. ncbi Adrenal incidentaloma
    Geoffrey B Thompson
    Department of Surgery, and Professor of Medicine, Mayo Medical School, Rochester, Minnesota 55905, USA
    Curr Opin Oncol 15:84-90. 2003
    ..Subclinical metabolic abnormalities associated with adrenal incidentalomas remain an area of intense clinical research...
  72. ncbi A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma
    A Buffet
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Service de Genetique, 20 rue Leblanc, Paris, France
    Horm Metab Res 44:359-66. 2012
    ..This genetic testing is of major importance for the follow-up of affected patients and for the genetic counselling of their families...
  73. ncbi The significance of angiogenesis in malignant pheochromocytomas
    Patrick P G M Rooijens
    Department of Surgery, Medical Centre Rijnmond Zuid, Location Clara, Rotterdam, The Netherlands
    Endocr Pathol 15:39-45. 2004
    ..However, the clinical significance of this prognostic marker is rather weak, because only 4 of the 19 malignant pheochromocytomas had microvessel density higher than this threshold of 28.5%...
  74. ncbi ACR Appropriateness Criteria on incidentally discovered adrenal mass
    Peter L Choyke
    National Cancer Institute, Bethesda, MD 20892, USA
    J Am Coll Radiol 3:498-504. 2006
    ..Adrenal biopsy should be reserved for cases in which the results of noninvasive techniques are equivocal...
  75. ncbi Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic Acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma
    James G Boyle
    Division of Cardiovascular and Medical Sciences, Western Infirmary, University of Glasgow, Glasgow G12 8TA, United Kingdom
    J Clin Endocrinol Metab 92:4602-8. 2007
    ....
  76. ncbi VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome
    Kaisa Salmenkivi
    Department of Pathology, Haartman Institute, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
    APMIS 111:458-64. 2003
    ..Normal medullary cells are immunohistochemically negative. Thus, low VEGF expression in pheochromocytomas favors a benign diagnosis...
  77. ncbi Pheochromocytoma: state-of-the-art and future prospects
    Emmanuel L Bravo
    Department of Nephrology and Hypertension, Cleveland Clinic Foundation, Cleveland Ohio 44195, USA
    Endocr Rev 24:539-53. 2003
    ....
  78. pmc Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy
    Lucia Martiniova
    Reproductive and Adult Endocrinology Program, Eunice Kennedy Shriver, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 6:e14678. 2011
    ..Subsequently, we evaluated the increased efficacy of chemotherapy combined with LB1...
  79. ncbi Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma
    Judith Favier
    INSERM, UMR970, Paris Cardiovascular Research Center, Paris, France
    Endocr Pathol 23:34-42. 2012
    ..Our results suggest that there is a strong rationale for anti-VEGF-based therapeutic strategies in malignant pheochromocytomas and paragangliomas, in particular in those associated with mutations in the SDHB gene...
  80. ncbi Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study
    Guido Di Dalmazi
    Endocrinology Unit, Department of Clinical Medicine, S Orsola Malpighi Hospital, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, Bologna, Italy
    Eur J Endocrinol 166:669-77. 2012
    ..Whether SCS leads to metabolic and cardiovascular diseases is still controversial...
  81. ncbi Uncommon adrenal masses: CT and MRI features with histopathologic correlation
    Ying Kun Guo
    Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
    Eur J Radiol 62:359-70. 2007
    ..Moreover, CT and MRI are highly accurate in localization of uncommon adrenal masses, and useful to guide surgical treatments...
  82. ncbi Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma
    Hiroka Takahashi
    Department of Pediatrics, St Luke s International Hospital, Chuo Ku, Tokyo, Japan
    Pediatr Blood Cancer 50:676-8. 2008
    ..Neither acute nor chronic graft-versus-host disease (GVHD) was observed. The patient remained in remission for 3 months after RIST until the second relapse. MIBG therapy combined with RIST warrants further trials...
  83. ncbi ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice
    Edwin W Lai
    Lombardi Cancer Comprehensive Center, Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA
    Cell Cycle 6:1946-50. 2007
    ..These data establish that increased ErbB-2 growth factor receptor signaling in the adrenal medulla can lead to PCC through combined influences on Pten, AKT andcyclin D1...
  84. ncbi Endoscopic adrenalectomy: an analysis of the transperitoneal and retroperitoneal approaches and results of a prospective follow-up study
    I Gockel
    Department of General and Abdominal Surgery, Johannes Gutenberg University, Langenbeckstrasse 1, 55101 Mainz, Germany
    Surg Endosc 19:569-73. 2005
    ..The aim of this study was to determine which of these is the optimal surgical technique in a prospectively designed analysis of a large series of patients operated on by a single team over a 10-year period...
  85. ncbi The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A
    Klaus Martin Schulte
    Department of Endocrine Surgery, King s College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
    J Clin Endocrinol Metab 95:E92-7. 2010
    ..A strong genotype-phenotype correlation results in major implications for the clinical approach. More information on less common mutations is needed to advance specific guidance...
  86. ncbi Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects
    V Morelli
    Unit of Endocrinology and Diabetology, Department of Medical Sciences, Universita degli Studi di Milano, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan
    Clin Endocrinol (Oxf) 73:161-6. 2010
    ..We aimed to investigate the accuracy of different SH diagnostic criteria in predicting the presence of complications...
  87. ncbi Should we use laparoscopic adrenalectomy for metastases? Scandinavian multicenter study
    Irina Pavlik Marangos
    Interventional Centre, Rikshospitalet University Hospital, Oslo, Norway
    J Surg Oncol 100:43-7. 2009
    ..Laparoscopic adrenalectomy for metastases is considered controversial. Multicenter retrospective study was performed to gain new knowledge in this issue...
  88. ncbi Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)
    M R Druce
    Department of Endocrinology, Barts and the London School of Medicine, London, UK
    Horm Metab Res 41:697-702. 2009
    ..We outline these four cases and review the theoretical background for this therapy, although the outcomes were relatively disappointing...
  89. pmc Adrenal schwannoma treated with laparoscopic surgery
    Naoyoshi Onoda
    Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
    JSLS 12:420-5. 2008
    ..We report a case of left adrenal schwannoma in a 62-year-old man, incidentally discovered on an abdominal computed tomography. It was successfully treated with laparoscopic adrenalectomy...
  90. ncbi Changing paradigms in the treatment of malignant pheochromocytoma
    Raymon H Grogan
    Department of Endocrine Surgery, University of California, San Francisco, CA 94143, USA
    Cancer Control 18:104-12. 2011
    ..Recently, however, the genetic and molecular changes involved in malignant pheochromocytoma have come to be understood...
  91. ncbi Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience
    Franco Casamassima
    Clinical Radiobiological Institute, University of Florence, Florence, Italy
    Int J Radiat Oncol Biol Phys 82:919-23. 2012
    ..To evaluate a retrospective single-institution outcome after hypofractionated stereotactic body radiotherapy (SBRT) for adrenal metastases...
  92. ncbi Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma
    Esther Korpershoek
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Pathol 217:597-604. 2009
    ..The mouse model should allow further studies into the pathogenesis of human malignant PCCs and into therapeutic strategies for these tumours...
  93. pmc Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma
    Graeme Eisenhofer
    Institute of Clinical Chemistry and Laboratory Medicine, University of Dresden, Dresden, Germany
    Am J Physiol Endocrinol Metab 295:E1223-33. 2008
    ....
  94. ncbi Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer
    Yoshiko Oshiro
    Department of Radiation Oncology, International Medical Center of Japan, Tokyo, Japan
    Am J Clin Oncol 34:249-53. 2011
    ..In this study, we evaluated the clinical results of radiotherapy performed for local control in patients with this disease...
  95. ncbi Schwannoma of the adrenal gland: report of two cases
    Sean K Lau
    Department of Pathology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Am J Surg Pathol 30:630-4. 2006
    ..Because of its rarity, schwannoma occurring at this particular site can pose problems in diagnosis and should be distinguished from other spindle cell lesions of the adrenal gland...
  96. ncbi Non-invasive evaluation of the incidentally detected indeterminate adrenal mass
    Mahmoud M Al-Hawary
    Department of Radiology, University of Michigan Hospitals, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0030, USA
    Best Pract Res Clin Endocrinol Metab 19:277-92. 2005
    ..e. the differentiation of benign from malignant masses). The imaging techniques and the algorithms that are used in our institution for the evaluation of incidentally detected adrenal mass will be described...
  97. ncbi Adrenal ganglioneuromas: incidentalomas with misleading clinical and imaging features
    Dimitrios Linos
    1st Surgical Clinic, Diagnostic and Therapeutic Center of Athens Hygeia, Athens, Greece
    Surgery 149:99-105. 2011
    ..Ganglioneuromas are benign neoplasms of the neural crest, occurring rarely in the adrenal glands. This study presents our experience regarding diagnostic and therapeutic management of these neoplasms and a review of the relevant literature...
  98. ncbi Synchronous presentation of primary non-small cell lung carcinoma and pheochromocytoma
    Edward P Chen
    Division of Cardiothoracic Surgery and General Surgery, Emory University Affiliated Hospitals, Atlanta, Georgia, USA
    Ann Thorac Surg 74:924-6. 2002
    ..This case illustrates the importance of establishing a firm diagnosis for all synchronously present adrenal lesions that are discovered in the setting of primary lung carcinoma...
  99. ncbi Denaturing high performance liquid chromatography detection of SDHB, SDHD, and VHL germline mutations in pheochromocytoma
    Goswin Y Meyer-Rochow
    Kolling Institute of Medical Research, Royal North Shore Hospital and University of Sydney, Australia
    J Surg Res 157:55-62. 2009
    ..The aim of this study was to evaluate denaturing high performance liquid chromatography (dHPLC) as a screening tool for the detection of germline mutations within VHL, SDHB, and SDHD in pheochromocytoma patients...
  100. ncbi Schwannomas of the left adrenal gland and posterior mediastinum
    Chwen Yi Yang
    Division of Endocrinology and Metabolism, Department of Medicine, Chi Mei Hospital, Tainan, Taiwan, ROC
    J Chin Med Assoc 72:83-7. 2009
    ..Total excision of benign schwannoma is associated with favourable outcome in patients...
  101. pmc Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma
    Sara Molatore
    Department of Pathology, Helmholtz Zentrum Munchen, 85764 Neuherberg, Germany
    Proc Natl Acad Sci U S A 107:18493-8. 2010
    ..These studies reveal clues to the molecular pathways involved in rat and human pheochromocytoma and identify previously unexplored biomarkers for clinical use...

Research Grants21

  1. PHEOCHROMOCYTOMAS FROM NEUROFIBROMATOSIS KNOCKOUT MICE
    Arthur Tischler; Fiscal Year: 2003
    ..4) To determine the status of neurofibromin in MPC cells and test the hypothesis that abnormal regulation of ras activity is responsible for neuronal differentiation in this model. ..
  2. CHROMAFFIN CELL PROLIFERATION IN NEOPLASTIC PROGRESSION
    Arthur Tischler; Fiscal Year: 2006
    ..The proposed studies will help to elucidate mechanisms that may be involved in the development and progression of pheochromocytomas. ..
  3. TRAINING PROGRAM IN CLINICAL RESEARCH
    David Schteingart; Fiscal Year: 2004
    ..abstract_text> ..
  4. Michigan Mentored Clinical Scholars Program
    David Schteingart; Fiscal Year: 2007
    ..On the basis of these resources, we are confident we can offer an outstanding pro_am for the training of clinical research scholars. ..
  5. MINORITY PREDOCTORAL FELLOWSHIP PROGRAM
    HECTOR MOBINE; Fiscal Year: 2008
    ..The findings may not only afford further appreciation of the pathophysiology and etiology of peripartum cardiomyopathy but also of general mechanisms in disease progression. [unreadable] [unreadable] [unreadable]..
  6. HEART IMAGING AGENTS--STRUCTURAL MECHANISTICS STUDY
    David Raffel; Fiscal Year: 2001
    ..Finally, [11C]- and [18F]-labeled polar derivatives of the psychostimulant methcathinone will be synthesized as potential NET markers and their in vitro NET affinities determined as the cloned human NET transporter. ..
  7. INHALATIONAL ANESTHETIC BINDING STUDIES
    Roderic Eckenhoff; Fiscal Year: 2007
    ..abstract_text> ..
  8. NFAT and MEF-2 Choreograph Bladder Wall Remodeling Following Partial Outlet Obstr
    STEPHEN ANTHONY ZDERIC; Fiscal Year: 2010
    ..New therapy to preserve and enhance native bladder function will help avoid the development of the end stage bladder. ..
  9. Homologous Recombination in a Secretory Mouse Cell Line
    AMY HARKINS; Fiscal Year: 2003
    ....
  10. Microarray analysis of thyroid neoplasm
    Martha Zeiger; Fiscal Year: 2004
    ..This will be performed using quantitative real-time RT-PCR on RNA samples from a panel of thyroid tumors. ..
  11. Interaction of amyloid beta and inhaled anesthetics
    Roderic Eckenhoff; Fiscal Year: 2006
    ..These studies will provide the feasibility to extend this hypothesis to animal models and ultimately to clinical studies of the interaction between anesthetics and neurodegeneration. ..
  12. Extracranial Stereotactic Radioablation in Lung Cancer
    Ronald McGarry; Fiscal Year: 2004
    ....
  13. MUTANT P53 GAIN OF FUNCTION IN TUMORIGENESIS
    Gerard Zambetti; Fiscal Year: 2007
    ..abstract_text> ..
  14. PERINATAL HYPOXIA: ADRENOCORTICAL-METABOLIC ADAPTATIONS
    Hershel Raff; Fiscal Year: 2006
    ..Characterization of the hypothalamic-pituitary-adrenal and metabolic adaptations to perinatal hypoxia can lead to new diagnostic approaches and therapies to minimize morbidity and mortality. ..
  15. HEART IMAGING AGENTS--STRUCTURAL MECHANISTICS STUDY
    David Raffel; Fiscal Year: 2004
    ..Finally, [11C]- and [18F]-labeled polar derivatives of the psychostimulant methcathinone will be synthesized as potential NET markers and their in vitro NET affinities determined as the cloned human NET transporter. ..
  16. Molecular Classification of Suspicious Thyroid Tumors
    Martha Zeiger; Fiscal Year: 2009
    ..abstract_text> ..
  17. Neurotrophic Factor & Neuronal Primary Responses Genes
    Harvey Herschman; Fiscal Year: 2004
    ..Finally, we will determine mechanisms by which (i) NGF induces UPAR and (ii) UPAR modulates NGF-driven neuron differentiation. ..
  18. Detecting Med Errors in Rural Hospitals Using Technology
    C Brown; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  19. Computer Aided Liver Lesion Detection Algorithm
    Lawrence Schwartz; Fiscal Year: 2005
    ..Clearly this is the first step in a process of development and if successful will lead to further efforts in automated detection and characterization. ..
  20. IMAGING COX-2 GENE EXPRESSION IN INFLAMMATION AND TUMORS
    Harvey Herschman; Fiscal Year: 2009
    ..Studies with this mouse will correlate optical and microPET imaging technologies. ..